NCCN eBulletin - NCCN Guidelines™ for Breast Cancer Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Breast Cancer and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) Chapter for Breast Cancer. The NCCN Guidelines™ for Breast Cancer are currently available as Version 2.2010.

The update to the NCCN Guidelines™ for Breast Cancer includes a new footnote added to page BINV-17, footnote h, which states "Limited studies document a progression free survival advantage of adding trastuzumab or lapatinib to aromatase inhibition in postmenopausal patients with ER-positive, HER2-positive disease. However, no overall survival advantage has been demonstrated."

The discussion section of the NCCN Guidelines for Breast Cancer and the NCCN Compendium™ Chapter for Breast Cancer have also been updated.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, and the NCCN Chemotherapy Order Templates™ please visit NCCN.org.

National Comprehensive Cancer Network

About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

NCCN Guidelines™ for Breast Cancer and NCCN Compendium™ Chapter for Breast Cancer Updated